Denmark

Scandion Oncology

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Scandion Oncology Drug SCO-101 Potentiates the Effect of Chemotherapy in the First Cohort in Chemo-Resistant Metastatic Colorectal Cancer

Lead Product(s): Endovion,Fluorouracil,Leucovorin

Therapeutic Area: Oncology Product Name: SCO-101

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 31, 2020

Details:

The main result is that 150 mg daily oral SCO-101 potentiates the effects of chemotherapy (FOLFIRI). Based on the safety data from this first cohort of patients, the Data Safety Monitoring Board has recommended to include 3 additional patients at 150 mg SCO-101 in order to get more details on the interactions between SCO-101 and FOLFIRI.

Symphogen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Servier Completes the Acquisition of Symphogen

Lead Product(s): Sym021

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Servier

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition June 04, 2020

Details:

As a result of this acquisition Symphogen becomes Servier’s center of excellence for antibodies, strengthening the Group’s pipeline in various therapeutic areas, including oncology.